Review article: safety of infliximab in clinical trials.

  title={Review article: safety of infliximab in clinical trials.},
  author={S B Hanauer},
  journal={Alimentary pharmacology & therapeutics},
  volume={13 Suppl 4},
  pages={16-22; discussion 38}
  • S B Hanauer
  • Published 1999 in Alimentary pharmacology & therapeutics
Infliximab, a chimeric monoclonal antibody to tumour necrosis factor-alpha, contains murine protein elements and targets the immune system, raising concerns about the potential for immune sensitization and immunosuppressive sequelae. However, long-standing inflammatory disease with high activity and chronic immunosuppressant therapy can also predispose patients to immunosuppressive sequelae. Patients with Crohn's disease, rheumatoid arthritis and other indications received single or multiple… CONTINUE READING
46 Citations
0 References
Similar Papers


Publications citing this paper.
Showing 1-10 of 46 extracted citations

Similar Papers

Loading similar papers…